Genome-wide search for inborn errors of IL-17 immunity underlying chronic mucocutaneous candidiasis

全基因组搜索慢性皮肤粘膜念珠菌病背后的 IL-17 免疫先天性错误

基本信息

  • 批准号:
    10446298
  • 负责人:
  • 金额:
    $ 50.85万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-11-14 至 2027-02-28
  • 项目状态:
    未结题

项目摘要

Project Summary Chronic mucocutaneous candidiasis (CMC) is characterized by lesions of the nails, skin, and oral and genital mucosae by the fungus Candida albicans. Autosomal recessive (AR) IL-17RA, IL-17RC, and ACT1 deficiencies, and autosomal dominant (AD) IL-17F deficiency underlie ‘isolated CMC’, while AR CARD9, ROR-g/gT, ZNF341, IL-12p40, and IL-12Rβ1 deficiencies, AD STAT3, IL6ST/GP130, and JNK1 deficiencies, and AD STAT1 gain-of- function (GOF) underlie ‘syndromic CMC’. Cells with IL-17RA, IL-17RC, ACT1, or JNK1 deficiency respond poorly to IL-17A and IL-17F. Cells with IL-17RA or ACT1 deficiency also respond poorly to IL-17E (IL-25). Patients with ROR-g/gT, ZNF341, STAT3, IL6ST, or JNK1 deficiency, or STAT1 GOF, display low proportions of IL-17A/IL-17F (IL-17A/F)-producing T cells. Since 2008, we have made major contributions to these discoveries that causally connected inborn errors of IL-17 immunity with CMC. Three outstanding enigmas are (i) the mechanisms by which STAT1 mutations can be GOF and by which they impair the development of IL-17 T cells, (ii) the mechanisms by which inborn errors of STAT3 that impair IL-17 production underlie CMC, while inborn errors of STAT3-activating cytokines IL-6, IL-21, and IL-23 apparently do not, and (iii) the genetic etiology of about half of the patients with isolated or syndromic CMC. We first intend to test the hypotheses that (a) STAT1 GOF mutations impair the dephosphorylation of nuclear STAT1 by disrupting the formation of antiparallel dimers, thereby preventing the accessibility of specific phosphatases, and that (b) excessive responses of T cells to IFN-a, IFN-g, and IL-27 collectively impair the development of Th17 cells. We then intend to analyze the production of IL-17 cytokines by leukocytes from patients with IL-6R, IL-21R, or IL-23R deficiency, in comparison with known etiologies of CMC, testing the hypothesis that the isolated disruption of IL-6, IL-21, or IL-23 only weakly impairs the development of Th17 and related IL-17-producing lymphocytes. We finally intend to discover novel CMC-causing genes using genome-wide (GW) approaches, based on GW linkage (GWL), and whole-exome or whole-genome sequencing (WES/WGS). On the three fronts, we have exciting preliminary results. We found (i) that all STAT1 variants tested are GOF due to impaired dephosphorylation by the tyrosine phosphatases TC-PTP and PTP1B, by disruption of antiparallel dimers formation; and the concomitant addition of STAT1-dependent cytokines IFN-a/b, IFN-g, and IL-27 inhibits the development of IL-17 T cells from naïve CD4+ T cells with STAT1 GOF; (ii) patients with AR IL- 6R or IL-23R deficiency and CMC, implying incomplete penetrance; and (iii) patients with syndromic CMC and mutations of cRel, RelB, MAP3K6 (also known as ASK2), ZNF375 (zDHHC5), or UBASH3B (TULA-2). From a biological standpoint, this research will provide new insights into the mechanisms of mucocutaneous immunity to fungi, while dissecting the molecular and cellular control of human IL-17. From a clinical angle, this work will provide new molecular diagnoses for patients and genetic counseling for families, while paving the way for new cytokine-based approaches in patients with CMC.
项目摘要 慢性皮肤粘膜念珠菌病(CMC)的特征是损害的指甲,皮肤,口腔和生殖器 被白色念珠菌感染。常染色体隐性(AR)IL-17 RA、IL-17 RC和ACT 1缺陷, 和常染色体显性(AD)IL-17 F缺乏是“孤立性CMC”的基础,而AR CARD 9,ROR-g/gT,ZNF 341, IL-12 p40和IL-12 R β1缺陷,AD STAT 3、IL 6ST/GP 130和JNK 1缺陷,以及AD STAT 1获得性 功能(GOF)是“综合征型CMC”的基础。具有IL-17 RA、IL-17 RC、ACT 1或JNK 1缺陷的细胞反应较差 IL-17A和IL-17F。具有IL-17 RA或ACT 1缺陷的细胞也对IL-17 E(IL-25)反应不良。患者 ROR-g/gT、ZNF 341、STAT 3、IL 6ST或JNK 1缺陷或STAT 1 GOF显示低比例的IL-17 A/IL-17 F (IL-17 A/F)-产生T细胞。自2008年以来,我们对这些发现做出了重大贡献, 将先天性IL-17免疫缺陷与CMC联系起来。三个突出的谜是(一)的机制, STAT 1突变可以是GOF,并通过其损害IL-17 T细胞的发育,(ii) 这些先天性STAT 3缺陷损害IL-17的产生是CMC的基础,而先天性STAT 3激活缺陷是CMC的基础。 细胞因子IL-6、IL-21和IL-23显然没有,和(iii)大约一半的患有 孤立或综合征CMC。我们首先打算检验以下假设:(a)STAT 1 GOF突变损害了 通过破坏反平行二聚体的形成,使细胞核STAT 1去磷酸化,从而阻止细胞凋亡。 特异性磷酸酶的可及性,以及(B)T细胞对IFN-a、IFN-g和IL-27的过度应答 共同损害Th 17细胞的发育。然后,我们打算分析IL-17细胞因子的产生, 与CMC的已知病因相比,来自IL-6 R、IL-21 R或IL-23 R缺乏患者的白细胞, 检验IL-6、IL-21或IL-23的单独破坏仅微弱损害以下发育的假设 Th 17和相关的IL-17产生淋巴细胞。最后,我们打算利用基因工程技术发现新的CMC致病基因。 全基因组(GW)方法,基于GW连锁(GWL)和全外显子组或全基因组测序 (WES/WGS)。在这三个方面,我们取得了令人兴奋的初步成果。我们发现(i)所有测试的STAT 1变体 是由于酪氨酸磷酸酶TC-PTP和PTP 1B的去磷酸化受损, 反平行二聚体形成;以及同时添加STAT 1依赖性细胞因子IFN-a/B、IFN-g和 IL-27抑制IL-17 T细胞从具有STAT 1 GOF的幼稚CD 4 + T细胞的发育;(ii)具有AR IL-27的患者 6 R或IL-23 R缺乏和CMC,意味着不完全的转移;和(iii)患有综合征CMC的患者, cRel、RelB、MAP 3 K6(也称为ASK 2)、ZNF 375(zDHHC 5)或UBASH 3B(TK-2)的突变。从 从生物学角度来看,这项研究将为皮肤粘膜免疫机制提供新的见解, 真菌,同时解剖人IL-17的分子和细胞控制。从临床角度来看,这项工作将 为患者提供新的分子诊断,为家庭提供遗传咨询,同时为新的 CMC患者中基于精氨酸的方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jean-Laurent Casanova其他文献

Jean-Laurent Casanova的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jean-Laurent Casanova', 18)}}的其他基金

Human Genetics of Tuberculosis
结核病的人类遗传学
  • 批准号:
    10430226
  • 财政年份:
    2021
  • 资助金额:
    $ 50.85万
  • 项目类别:
Human Genetics of Tuberculosis
结核病的人类遗传学
  • 批准号:
    10268806
  • 财政年份:
    2021
  • 资助金额:
    $ 50.85万
  • 项目类别:
Inborn errors of immunity in patients with life-threatening COVID-19
危及生命的 COVID-19 患者先天性免疫缺陷
  • 批准号:
    10655372
  • 财政年份:
    2021
  • 资助金额:
    $ 50.85万
  • 项目类别:
Inborn errors of immunity in patients with life-threatening COVID-19
危及生命的 COVID-19 患者先天性免疫缺陷
  • 批准号:
    10278180
  • 财政年份:
    2021
  • 资助金额:
    $ 50.85万
  • 项目类别:
Inborn errors of immunity in patients with life-threatening COVID-19
危及生命的 COVID-19 患者先天性免疫缺陷
  • 批准号:
    10449276
  • 财政年份:
    2021
  • 资助金额:
    $ 50.85万
  • 项目类别:
Human Genetics of Tuberculosis
结核病的人类遗传学
  • 批准号:
    10621305
  • 财政年份:
    2021
  • 资助金额:
    $ 50.85万
  • 项目类别:
Molecular and cellular basis of epidermodysplasia verruciformis
疣状表皮发育不良的分子和细胞基础
  • 批准号:
    10561607
  • 财政年份:
    2020
  • 资助金额:
    $ 50.85万
  • 项目类别:
Monogenic basis of resistance to SARS-CoV2 and predisposition to severe COVID-19
抗 SARS-CoV2 的单基因基础和严重 COVID-19 的易感性
  • 批准号:
    10159675
  • 财政年份:
    2020
  • 资助金额:
    $ 50.85万
  • 项目类别:
Molecular and cellular basis of epidermodysplasia verruciformis
疣状表皮发育不良的分子和细胞基础
  • 批准号:
    10352425
  • 财政年份:
    2020
  • 资助金额:
    $ 50.85万
  • 项目类别:
Molecular and cellular basis of epidermodysplasia verruciformis
疣状表皮发育不良的分子和细胞基础
  • 批准号:
    9887337
  • 财政年份:
    2020
  • 资助金额:
    $ 50.85万
  • 项目类别:

相似海外基金

Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
  • 批准号:
    479128
  • 财政年份:
    2023
  • 资助金额:
    $ 50.85万
  • 项目类别:
    Operating Grants
Pathogenic Autoantibodies with Specificity for Aberrant Glycoproteins: Assessment of a Therapeutic Target in an Autoimmune Disease
具有异常糖蛋白特异性的致病性自身抗体:自身免疫性疾病治疗靶点的评估
  • 批准号:
    10581585
  • 财政年份:
    2020
  • 资助金额:
    $ 50.85万
  • 项目类别:
Pathogenic Autoantibodies with Specificity for Aberrant Glycoproteins: Assessment of a Therapeutic Target in an Autoimmune Disease
具有异常糖蛋白特异性的致病性自身抗体:自身免疫性疾病治疗靶点的评估
  • 批准号:
    10359090
  • 财政年份:
    2020
  • 资助金额:
    $ 50.85万
  • 项目类别:
Pathogenic Autoantibodies with Specificity for Aberrant Glycoproteins: Assessment of a Therapeutic Target in an Autoimmune Disease
具有异常糖蛋白特异性的致病性自身抗体:自身免疫性疾病治疗靶点的评估
  • 批准号:
    10117072
  • 财政年份:
    2020
  • 资助金额:
    $ 50.85万
  • 项目类别:
Clarify the pathological mechanism for autoimmune encephalitis using recombinant autoantibodies
利用重组自身抗体阐明自身免疫性脑炎的病理机制
  • 批准号:
    19K22548
  • 财政年份:
    2019
  • 资助金额:
    $ 50.85万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Autoantibodies in patients with autoimmune pancreatitis: its pathophysiological roles and clinical significance
自身免疫性胰腺炎患者自身抗体的病理生理作用及临床意义
  • 批准号:
    18K07958
  • 财政年份:
    2018
  • 资助金额:
    $ 50.85万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A comprehensive study of antiphospholipid antibodies in autoimmune diseases for which existing autoantibodies are unspecified
现有自身抗体未明确的自身免疫性疾病中抗磷脂抗体的综合研究
  • 批准号:
    16K10031
  • 财政年份:
    2016
  • 资助金额:
    $ 50.85万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular pathology of autoimmune hemorrhaphilia XIII/13; analysis of anti-factor XIII autoantibodies and elucidation of the mechanism of their generation
自身免疫性血友病XIII/13的分子病理学;
  • 批准号:
    16K09820
  • 财政年份:
    2016
  • 资助金额:
    $ 50.85万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The study of anti-endothelial cell autoantibodies in patients with autoimmune encephalitis
自身免疫性脑炎患者抗内皮细胞自身抗体的研究
  • 批准号:
    15K09337
  • 财政年份:
    2015
  • 资助金额:
    $ 50.85万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Pathogenesis of Autoimmune Hemorrhaphilia XIII/13: Analysis of Anti-FXIII/13 Autoantibodies and Elucidation of Their Generation Mechanisms
自身免疫性血友病XIII/13的发病机制:抗FXIII/13自身抗体的分析及其产生机制的阐明
  • 批准号:
    25461444
  • 财政年份:
    2013
  • 资助金额:
    $ 50.85万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了